N/A
N=18
The Effects of Watermelon Juice Supplementation on Postprandial Vascular Endothelial Function
Endothelial Dysfunction
Bottom Line
View on ClinicalTrials.gov: NCT04092439 ↗Enrolled (actual)
18
Serious AEs
0.0%
Results posted
Jul 2024
Primary outcome: Primary: Endothelial Function — 3.31; 3.53 millimeters
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Watermelon Juice (Dietary_supplement)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Pennington Biomedical Research Center
- Primary completion
- Mar 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Endothelial Function |
3.31; 3.53 | — |
| SECONDARY Postprandial Blood Flow |
36.0; 51.0 | — |
Summary
The purpose of this study is to test if watermelon juice supplementation improves vascular dysfunction experience during hyperglycemia.
Eligibility Criteria
Inclusion Criteria
- Capable and willing to give written informed consent and understand inclusion and exclusion criteria.
- 18-40 years of age
- BMI between 18-29.9 kg/m2
- Willing to allow researchers to draw blood and conduct imaging (DXA) for research purposes.
Exclusion Criteria
- Evidence or self-reported history of type 1 or 2 diabetes mellitus
- Self-reported family history of type 2 diabetes (first degree relative with type 2 diabetes)
- Evidence or self-report history of deep vein thrombosis, pulmonary embolism, cardiovascular, peripheral vascular, cerebral vascular, pulmonary, or renal disease
- Allergy to watermelon
- Use of medication known to influence study outcomes, such as:
- Insulin
- Anti-diabetics (metformin)
- Corticosteroids
- Beta-blockers
- Anti-coagulates
- Use of supplements known to influence study outcomes, such as;
- Beta-alanine
- L-arginine
- L-citrulline
- Active smoking
Data sourced from ClinicalTrials.gov (NCT04092439). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.